del Boz J, et al. - Authors assessed adjusting the dose of oral oxybutynin (OOx) for hyperhidrosis according to the time of year. They performed a prospective study of patients who began OOx for hyperhidrosis (HH) between 2007 and 2017, and maintained treatment for at least 1 year, with a progressively increasing dose. With no differences among groups, the frequency of adverse effects (AE) was 74.6%. In most patients, the HH could be controlled without requiring the same dose of OOx throughout the year. Experts noted the AE of OOx to be dose-dependent, seemingly it was reasonable to vary it according to the time of year.